A prespecified VESALIUS-CV analysis found a 20% reduction in mortality with Amgen’s Repatha among more than 12,000 high-risk adults without a previous heart attack or stroke, strengthening the case for intensive LDL lowering before the first major cardiovascular event.
Sandoz gains ex-China commercialization rights to an initial biosimilar portfolio while Henlius retains development, manufacturing and supply responsibilities under a collaboration worth up to $322 million.
Amgen has expanded its direct-to-patient program, AmgenNow, to include Aimovig (erenumab-aooe) and Amjevita (adalimumab-atto), each now available at a flat monthly price of $299 for eligible U.S. patients. This development forms part of Amgen’s broader agreement with the Trump Administration, satisfying conditions laid out in the President’s July 31 policy letter and positioning the company